The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.
One company value investors might notice is Option Care Health (OPCH - Free Report) . OPCH is currently sporting a Zacks Rank #2 (Buy), as well as an A grade for Value. The stock holds a P/E ratio of 15.09, while its industry has an average P/E of 19.00. Over the past year, OPCH's Forward P/E has been as high as 25.75 and as low as 14.74, with a median of 18.54.
Another notable valuation metric for OPCH is its P/B ratio of 3.38. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. This stock's P/B looks solid versus its industry's average P/B of 4.74. Over the past year, OPCH's P/B has been as high as 4.27 and as low as 2.59, with a median of 3.66.
Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. OPCH has a P/S ratio of 0.64. This compares to its industry's average P/S of 1.46.
Finally, investors should note that OPCH has a P/CF ratio of 15.67. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 33.21. Within the past 12 months, OPCH's P/CF has been as high as 21.37 and as low as 13.58, with a median of 18.42.
Value investors will likely look at more than just these metrics, but the above data helps show that Option Care Health is likely undervalued currently. And when considering the strength of its earnings outlook, OPCH sticks out as one of the market's strongest value stocks.
BANNOCKBURN, Ill., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced that John Rademacher, CEO and Meenal Sethna, CFO, will participate in the following up coming investor conferences:
Morgan Stanley 24th Annual Global Healthcare Conference, being held in New York City, on Tuesday, September 15, 2026 at 10:45am ET/9:45am CT.Deutsche Bank 2026 Healthcare Summit, being held in New York City, Wednesday, September 16, 2026. Webcast links and related presentation materials, if applicable, will be available online at https://investors.optioncarehealth.com.
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Option Care (OPCH) or Chemed (CHE). But which of these two stocks presents investors with the better value opportunity right now?
The Zacks Medical – Outpatient and Home Healthcare industry is undergoing a rapid transition toward digital modes of care delivery. Demand for telemedicine platforms and artificial intelligence (AI)-powered medical solutions has increased significantly in recent years. At the same time, the growing global aging population is encouraging many healthcare providers, which have traditionally been less technology-focused, to adopt tech-enabled offerings to remain competitive. Per Grand View Research, the global home healthcare market was estimated at $485.3 billion in 2025 and is anticipated to grow from $504.8 billion in 2026 to $1015.8 billion by 2033, at a CAGR of 10.5%. Rising healthcare costs are another key factor prompting MedTech companies to accelerate their shift toward digital healthcare.
Rising dependence on telehealth and AI is likely to help the industry thrive in the near term. DaVita Inc. (DVA - Free Report) , LifeStance Health Group, Inc. (LFST - Free Report) , Option Care Health, Inc. (OPCH - Free Report) and Aveanna Healthcare Holdings Inc. (AVAH - Free Report) are likely to gain from the prospects.
Industry Description The industry includes companies delivering ambulatory care in outpatient settings or at home, using advanced technologies for diagnosis, treatment and rehabilitation. Key players operate HMO medical centers, dialysis units and other outpatient facilities. Both payers and providers are witnessing steady growth, supported by ongoing service innovation and increasing demand for care outside traditional hospital settings. The continued shift toward value-based care models and the growing integration of technology across healthcare are creating opportunities for further expansion and are expected to support long-term industry growth. However, reimbursement pressures and elevated operating costs remain concerns for the industry's outlook.
Major Trends Shaping Outpatient and Home Healthcare Industry Aging Population: One of the primary drivers of the home healthcare market is the aging population. As people live longer, demand is growing for services related to chronic disease management, rehabilitation and daily living assistance. The rising elderly population is expected to increase the need for home healthcare services. Older adults also tend to prefer receiving appropriate healthcare services in the familiar and comfortable setting of their homes.
Cost Effectiveness: A key advantage of outpatient clinics is cost-effectiveness. Outpatient facilities generally do not require overnight stays and can offer a broad spectrum of diagnostic services, treatments and minor surgical procedures, often at lower costs than inpatient settings. Financial incentives, including health plans and government payment policies that support appropriate services in lower-cost settings, have also been driving outpatient care.
Home-based care can further generate healthcare savings by helping reduce avoidable emergency room visits, hospitalizations and readmissions. The continued emphasis on delivering appropriate care in lower-cost settings should support demand for outpatient and home-based services.
AI’s Growing Role: AI is playing an increasingly important role in healthcare, including remote patient monitoring and data analysis. Connected medical devices can collect patients' health information and make it available to healthcare providers, while AI-based tools can help identify changes in patient conditions and support timely intervention. AI can also simplify complex home care plans by assisting caregivers, providers and patients with care coordination and scheduling. Home healthcare providers are also using automation for administrative functions such as documentation, billing and workforce management, helping improve operational efficiency amid workforce constraints.
Technological Advancements: Virtual assistants and chatbots can help patients obtain information about their care and make more informed decisions. Integration with electronic health records can also help patients access health information, communicate with providers and manage appointments. Digital tools can further support adherence through medication, exercise and other care-plan reminders.
Home healthcare can benefit from Medicare and other payer coverage of eligible services delivered in patients' homes. Telehealth, remote monitoring and connected technologies are becoming increasingly integrated into healthcare delivery. CMS also introduced new remote therapeutic monitoring codes for 2026. Meanwhile, hospital-at-home continues to gain traction, with federal waivers and flexibilities for CMS' Acute Hospital Care at Home initiative extended through Sept. 30, 2030.
Staffing Shortages: Staffing shortages remain a structural challenge in U.S. healthcare, particularly in home-based care. Growing demand for caregivers, coupled with turnover and the need to replace workers leaving the occupation, continues to strain workforce availability. Rising labor costs can also pressure providers, particularly when reimbursement does not keep pace with expenses. Although technology and workflow automation can improve staff productivity and reduce administrative burdens, they cannot fully offset shortages of frontline workers in labor-intensive outpatient and home healthcare settings.
Zacks Industry Rank The Zacks Medical - Outpatient and Home Healthcare industry falls within the broader Zacks Medical sector. It has a Zacks Industry Rank #52, which places it in the top 21% of nearly 250 Zacks industries.
The group’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates encouraging near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Before we present a few outpatient home health stocks that you may want to consider for your portfolio, let’s take a look at the industry’s recent stock market performance and valuation picture.
Industry's Stock Market Performance The industry has outperformed its sector, but underperformed the S&P 500 Composite in the past year.
The industry has gained 19% over this period compared with the S&P 500’s rise of 21.6% and the broader sector’s growth of 12.5%.
One Year Price Performance
Image Source: Zacks Investment Research
Industry's Current Valuation Based on the forward 12-month price-to-earnings (P/E), commonly used for valuing medical stocks, the industry is currently trading at 19.1X compared with the S&P 500’s 20.5X and the sector’s 21.6X.
Over the last five years, the industry has traded as high as 22.6X and as low as 16.1X, with the median being at 19.3X, as the charts below show.
Price-to-Earnings Forward Twelve Months (F12M)
Image Source: Zacks Investment Research
Price-to-Earnings Forward Twelve Months (F12M)
Image Source: Zacks Investment Research
4 Outpatient and Home Healthcare Stocks to Watch LifeStance: A renowned provider of outpatient mental healthcare, LifeStance, reported second-quarter 2026 results this month, wherein it recorded a solid uptick in revenues. Its clinician base and visit volumes also improved during the quarter. LFST carries a Zacks Rank #2 (Buy).
For this Scottsdale, AZ-based company, the Zacks Consensus Estimate for 2026 revenues suggests growth of 19.7%. The same for earnings indicates a surge of 700%.
Image Source: Zacks Investment Research
The company’s debt/capital ratio of 14.92% compares favorably with the industry’s 39.53%.
Option Care Health: Option Care Health is a renowned independent provider of home and alternate site infusion services. Last month, the company reported second-quarter 2026 results, wherein it recorded an uptick in its net revenues and bottom line. Per management, the results reflected the company’s solid operational execution and the positive impact of its 2026 strategic initiatives. OPCH presently carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
For this Bannockburn, IL-based company, the Zacks Consensus Estimate for 2026 revenues suggests growth of 1.9%. The same for earnings indicates an increase of 8.7%.
Image Source: Zacks Investment Research
The company’s earnings yield of 7.8% compares favorably with the industry’s 4.7%.
Aveanna: It is a renowned diversified home care platform focused on providing care to medically complex, high-cost patient populations. This month, the company announced its second-quarter 2026 results, wherein it registered a solid uptick in its revenues. Per management, the results emphasize the strength of the company’s operating model and the continued success of the Preferred Payor and Government Affairs strategies. AVAH presently carries a Zacks Rank of 2.
For this Atlanta, GA-based company, the Zacks Consensus Estimate for 2026 revenues suggests growth of 10.6%. The same for earnings indicates an increase of 33.3%.
Image Source: Zacks Investment Research
The company’s earnings yield of 5.8% compares favorably with the industry’s 4.7%.
DaVita: This renowned global comprehensive kidney care provider announced a new value-based care agreement with Humana this month. The partnership aims to deliver comprehensive, coordinated care to Humana Medicare Advantage members with chronic kidney disease stages 3B–5. The same month, DVA reported second-quarter 2026 results. The company registered an uptick in its top and bottom lines and revenue per treatment during the quarter. Solid revenues from both sources and a per-day increase in total U.S. dialysis treatments on a sequential basis were also seen. An uptick in normalized non-acquired treatment was also recorded. On the earnings call, management highlighted plans to deploy expanded hemodialysis across its network after securing an adequate supply of newly approved dialyzers. DVA carries a Zacks Rank #3 (Hold).
For this Denver, CO-based company, the Zacks Consensus Estimate for 2026 revenues suggests growth of 4.7%. The same for earnings indicates an increase of 35.2%.
Image Source: Zacks Investment Research
The company’s earnings yield of 8.2% compares favorably with the industry’s 4.7%.
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
One stock to keep an eye on is Option Care Health (OPCH - Free Report) . OPCH is currently holding a Zacks Rank #2 (Buy) and a Value grade of A. The stock has a Forward P/E ratio of 15.09. This compares to its industry's average Forward P/E of 19.27. OPCH's Forward P/E has been as high as 25.75 and as low as 14.74, with a median of 18.54, all within the past year.
Investors should also recognize that OPCH has a P/B ratio of 3.38. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 4.76. Within the past 52 weeks, OPCH's P/B has been as high as 4.27 and as low as 2.59, with a median of 3.66.
Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. OPCH has a P/S ratio of 0.62. This compares to its industry's average P/S of 1.43.
Finally, investors should note that OPCH has a P/CF ratio of 15.67. This metric takes into account a company's operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook. OPCH's P/CF compares to its industry's average P/CF of 33.33. Over the past 52 weeks, OPCH's P/CF has been as high as 21.37 and as low as 13.58, with a median of 18.42.
These are just a handful of the figures considered in Option Care Health's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that OPCH is an impressive value stock right now.
Investors with an interest in Medical - Outpatient and Home Healthcare stocks have likely encountered both Option Care (OPCH - Free Report) and The Pennant Group, Inc. (PNTG - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Right now, Option Care is sporting a Zacks Rank of #2 (Buy), while The Pennant Group, Inc. has a Zacks Rank of #3 (Hold). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that OPCH is likely seeing its earnings outlook improve to a greater extent. But this is only part of the picture for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
OPCH currently has a forward P/E ratio of 12.65, while PNTG has a forward P/E of 29.04. We also note that OPCH has a PEG ratio of 1.24. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. PNTG currently has a PEG ratio of 2.23.
Another notable valuation metric for OPCH is its P/B ratio of 2.81. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, PNTG has a P/B of 3.36.
These are just a few of the metrics contributing to OPCH's Value grade of A and PNTG's Value grade of C.
OPCH sticks out from PNTG in both our Zacks Rank and Style Scores models, so value investors will likely feel that OPCH is the better option right now.
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.
One stock to keep an eye on is Option Care Health (OPCH - Free Report) . OPCH is currently sporting a Zacks Rank #2 (Buy), as well as an A grade for Value. The stock holds a P/E ratio of 15.09, while its industry has an average P/E of 19.19. OPCH's Forward P/E has been as high as 25.75 and as low as 14.74, with a median of 18.54, all within the past year.
Investors will also notice that OPCH has a PEG ratio of 1.40. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. OPCH's industry has an average PEG of 1.48 right now. Over the past 52 weeks, OPCH's PEG has been as high as 2.97 and as low as 1.37, with a median of 1.75.
Another notable valuation metric for OPCH is its P/B ratio of 3.38. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 4.84. Over the past 12 months, OPCH's P/B has been as high as 4.27 and as low as 2.59, with a median of 3.66.
Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. OPCH has a P/S ratio of 0.62. This compares to its industry's average P/S of 1.44.
Finally, we should also recognize that OPCH has a P/CF ratio of 15.67. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 35.19. Over the past year, OPCH's P/CF has been as high as 21.37 and as low as 13.58, with a median of 18.42.
These are just a handful of the figures considered in Option Care Health's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that OPCH is an impressive value stock right now.
Amundi reduced its holdings in Option Care Health, Inc. (NASDAQ:OPCH – Free Report) by 5.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 709,607 shares of the company’s stock after selling 38,525 shares during the quarter. Amundi owned 0.45% of Option Care Health worth $19,103,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of OPCH. Durable Capital Partners LP boosted its stake in Option Care Health by 134.2% in the 2nd quarter. Durable Capital Partners LP now owns 8,237,577 shares of the company’s stock worth $267,557,000 after purchasing an additional 4,720,988 shares during the period. Fuller & Thaler Asset Management Inc. grew its holdings in shares of Option Care Health by 12.1% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 6,958,800 shares of the company’s stock worth $221,707,000 after buying an additional 752,058 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in Option Care Health by 6.2% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,248,425 shares of the company’s stock valued at $135,355,000 after buying an additional 247,118 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Option Care Health by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,876,856 shares of the company’s stock valued at $104,368,000 after buying an additional 36,208 shares during the last quarter. Finally, Southpoint Capital Advisors LP lifted its stake in Option Care Health by 20.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 3,600,000 shares of the company’s stock valued at $96,912,000 after acquiring an additional 600,000 shares in the last quarter. 98.05% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Option Care Health In other news, Director Timothy P. Sullivan bought 24,154 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was acquired at an average cost of $20.69 per share, for a total transaction of $499,746.26. Following the purchase, the director owned 73,383 shares of the company’s stock, valued at approximately $1,518,294.27. This trade represents a 49.06% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 1.70% of the company’s stock.
Wall Street Analyst Weigh In A number of research firms have weighed in on OPCH. Stephens reaffirmed an “equal weight” rating and set a $24.00 price target (down from $30.00) on shares of Option Care Health in a research report on Friday, July 17th. Barrington Research cut their price objective on shares of Option Care Health from $42.00 to $32.00 and set an “outperform” rating on the stock in a research report on Friday, May 1st. UBS Group restated a “buy” rating on shares of Option Care Health in a report on Tuesday, June 16th. Wall Street Zen raised shares of Option Care Health from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, TD Cowen cut their price target on shares of Option Care Health from $37.00 to $23.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Seven investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $29.92.
Check Out Our Latest Research Report on OPCH
Option Care Health Price Performance NASDAQ:OPCH opened at $23.69 on Wednesday. The stock has a market capitalization of $3.55 billion, a PE ratio of 17.81, a P/E/G ratio of 1.41 and a beta of 0.65. Option Care Health, Inc. has a 1-year low of $18.01 and a 1-year high of $36.80. The firm has a fifty day simple moving average of $21.59 and a 200 day simple moving average of $26.60. The company has a current ratio of 1.47, a quick ratio of 0.98 and a debt-to-equity ratio of 0.91.
Option Care Health (NASDAQ:OPCH – Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.02. Option Care Health had a net margin of 3.68% and a return on equity of 18.74%. The firm had revenue of $1.44 billion for the quarter, compared to analyst estimates of $1.42 billion. During the same period in the prior year, the firm posted $0.41 earnings per share. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. Option Care Health has set its FY 2026 guidance at 1.850-1.920 EPS. On average, research analysts expect that Option Care Health, Inc. will post 1.64 EPS for the current fiscal year.
Option Care Health Company Profile (Free Report)
Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.
Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.
Featured Articles Five stocks we like better than Option Care Health System Upgrade: First Internet Bancorp Options Surge AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push The AI Chip Blockade Is Creating a Shadow Market Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter Want to see what other hedge funds are holding OPCH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Option Care Health, Inc. (NASDAQ:OPCH – Free Report).
Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEVirtual Reality Stocks To Consider – August 3rd
NEXT HEADLINE »Top Small Cap Stocks To Watch Now – August 3rd
Option Care Health Stock is Making a Healthy PullbackOption Care Health NASDAQ: OPCH reported second-quarter 2026 results that exceeded its internal expectations, with revenue, adjusted EBITDA and adjusted earnings per share all improving sequentially. The home and alternate-site infusion provider maintained its full-year revenue outlook while narrowing its adjusted EBITDA and EPS guidance ranges.
Revenue totaled $1.4 billion, up 2% from a year earlier and 7% from the first quarter, according to Executive Vice President and Chief Financial Officer Meenal Sethna. Adjusted EBITDA rose 3% year over year and 12% sequentially to $117.5 million, while adjusted EPS increased $0.04 from the prior-year period to $0.45. The company generated $184 million in operating cash flow during the quarter.
Get Option Care Health alerts:
President and Chief Executive Officer John Rademacher said the results reflected operational execution and the company’s strategic initiatives, though he said management sees additional opportunities to improve productivity, patient access and growth.
Acute Growth and Chronic Portfolio Trends Rademacher said Option Care’s acute therapy portfolio delivered high-single-digit organic revenue growth for a second consecutive quarter. The company saw sequential and year-over-year growth across key acute therapeutic categories and in the number of patients served.
“Our ability to consistently deliver for providers and their patients drove another quarter of above-market, high-single-digit revenue growth,” Rademacher said, adding that the company expects acute therapies to continue growing faster than the broader industry as it expands hospital and health-system partnerships.
Within chronic therapies, quarterly revenue was flat from a year earlier but increased by high single digits sequentially. The company reported sequential and year-over-year revenue growth in its immunoglobulin and neurology, or IG Neuro, portfolio, as well as growth in its rare and orphan portfolio.
The chronic inflammatory disease, or CID, portfolio began to stabilize after a first-quarter reset, with patient census increasing sequentially in the second quarter. Management expects to continue expanding the CID patient census through the remainder of 2026, while monitoring product mix and the patient base.
Sethna reiterated that the company’s 2026 projections include expected CID-related pressure of about 600 basis points on year-over-year revenue and a $55 million headwind to gross profit. She also said STELARA and related biosimilars are still expected to account for less than 1% of company net revenue and gross profit in 2026.
Margins, Cost Initiatives and Technology Investments Gross profit dollars increased 2% sequentially but declined slightly from the prior-year quarter. SG&A expense fell 3% year over year to about 11% of revenue, driven primarily by lower indirect labor costs, expense controls and lower variable compensation, Sethna said. The company continues to invest in commercial resources intended to support future growth.
Management said it is deploying technology, automation and artificial intelligence tools across areas including patient onboarding, claims processing, communications, nurse scheduling, delivery routing and field productivity. Rademacher said the company is combining these tools with experienced clinical teams to improve authorizations, claims submission and operational efficiency.
Sethna told analysts that the company’s outlook is not primarily dependent on administrative cost cuts. Instead, she cited commercial productivity, recovery in CID patient census, technology deployment, procurement initiatives and payer-related site-of-care programs as contributors to expected second-half improvement.
Option Care added five ambulatory infusion facilities during the second quarter. Visits at its facilities increased more than 20% year over year, and more than 35% of nursing visits were conducted in an infusion suite or clinic during the quarter, Rademacher said.
Capital Allocation and Updated Outlook The company repurchased $150 million of its shares during the quarter, representing nearly 5% of shares outstanding, according to Sethna. The repurchase reduced remaining authorization to $525 million. Option Care ended the quarter with net debt leverage of 2.1 times.
Management said its capital-allocation priorities remain organic investments in growth, capacity and cost optimization; periodic share repurchases; and potential acquisitions focused on portfolio adjacencies and tuck-in opportunities.
Full-year 2026 revenue guidance was maintained at $5.675 billion to $5.775 billion. Adjusted EBITDA guidance was narrowed to $480 million to $495 million. Adjusted EPS guidance was narrowed to $1.85 to $1.92. Operating cash flow is still expected to be at least $320 million. Net interest expense is projected at $50 million to $55 million, and the full-year tax rate is expected to be 26% to 28%. For the third quarter, Option Care expects sequential revenue growth in the low- to mid-single-digit range and sequential adjusted EBITDA growth in the mid-single-digit range. Sethna said the company expects seasonal growth to continue through the year, with the fourth quarter typically representing its largest quarter.
Market Access and Long-Term Positioning Rademacher said the company is pursuing additional pharmaceutical manufacturer partnerships, including rare and orphan therapies. Some newly added therapies are not expected to begin service until late 2026 or early 2027, and management said its current outlook is principally based on the existing portfolio and expected momentum rather than a substantial contribution from unlaunched products.
Regarding a CMS proposal to expand Medicare coverage for certain home infusion pumps and drugs beginning in 2027, Rademacher said the proposal involves a narrow set of therapies and is not expected to be financially material. He said the company supports broader access to home and alternate-site infusion care, which it believes can reduce total healthcare costs.
Management also said it has not seen a significant impact from white-bagging practices. Rademacher noted that Option Care remains broadly in network with payers and PBMs and continues to pursue site-of-care initiatives with national and regional health plans.
“While we posted improved second quarter results, there is still work to do,” Rademacher said in closing. “However, we believe the actions we have taken so far, combined with the strength of our clinical platform and market position, provide a strong foundation to re-accelerate our long-term growth trajectory.”
About Option Care Health (NASDAQ:OPCH)Option Care Health NASDAQ: OPCH is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.
Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry's most experienced home infusion businesses.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Option Care Health Right Now?Before you consider Option Care Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Option Care Health wasn't on the list.
While Option Care Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Option Care (OPCH - Free Report) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +7.14%. A quarter ago, it was expected that this infusion and home care services company would post earnings of $0.37 per share when it actually produced earnings of $0.4, delivering a surprise of +8.11%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Option Care, which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, posted revenues of $1.44 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.68%. This compares to year-ago revenues of $1.42 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Option Care shares have lost about 29.4% since the beginning of the year versus the S&P 500's gain of 8.5%.
What's Next for Option Care?While Option Care has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Option Care was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.48 on $1.45 billion in revenues for the coming quarter and $1.83 on $5.71 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Outpatient and Home Healthcare is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, U.S. Physical Therapy (USPH - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 5.
This physician staffing services company is expected to post quarterly earnings of $0.85 per share in its upcoming report, which represents a year-over-year change of +4.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
U.S. Physical Therapy's revenues are expected to be $213.4 million, up 8.1% from the year-ago quarter.
BANNOCKBURN, Ill., July 29, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the second quarter ended June 30, 2026.
Dimensional Fund Advisors LP increased its stake in Option Care Health, Inc. (NASDAQ:OPCH – Free Report) by 0.9% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,876,856 shares of the company’s stock after buying an additional 36,208 shares during the period. Dimensional Fund Advisors LP owned 2.47% of Option Care Health worth $104,368,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Durable Capital Partners LP raised its stake in Option Care Health by 134.2% during the second quarter. Durable Capital Partners LP now owns 8,237,577 shares of the company’s stock valued at $267,557,000 after buying an additional 4,720,988 shares during the last quarter. Southpoint Capital Advisors LP purchased a new stake in shares of Option Care Health in the fourth quarter worth $95,580,000. Sumitomo Mitsui Trust Group Inc. bought a new position in shares of Option Care Health during the first quarter valued at $70,287,000. Norges Bank bought a new position in shares of Option Care Health during the fourth quarter valued at $61,787,000. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Option Care Health in the 4th quarter worth about $38,559,000. Institutional investors own 98.05% of the company’s stock.
Analyst Upgrades and Downgrades Several analysts recently commented on OPCH shares. UBS Group reissued a “buy” rating on shares of Option Care Health in a research report on Tuesday, June 16th. Morgan Stanley set a $28.00 target price on shares of Option Care Health in a research note on Wednesday, May 6th. TD Cowen cut their price target on shares of Option Care Health from $37.00 to $23.00 and set a “hold” rating on the stock in a report on Friday, May 1st. Barrington Research decreased their price objective on shares of Option Care Health from $42.00 to $32.00 and set an “outperform” rating for the company in a report on Friday, May 1st. Finally, Truist Financial set a $30.00 target price on Option Care Health in a research note on Friday, May 1st. Eight equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Option Care Health has an average rating of “Moderate Buy” and an average target price of $30.08.
Check Out Our Latest Research Report on Option Care Health
Option Care Health Price Performance OPCH opened at $22.48 on Wednesday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.07 and a current ratio of 1.64. The stock has a market capitalization of $3.53 billion, a P/E ratio of 17.43, a P/E/G ratio of 1.21 and a beta of 0.65. The company’s 50-day simple moving average is $21.39 and its two-hundred day simple moving average is $26.94. Option Care Health, Inc. has a 52-week low of $18.01 and a 52-week high of $36.80.
Option Care Health (NASDAQ:OPCH – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.03. Option Care Health had a net margin of 3.64% and a return on equity of 18.17%. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.39 billion. During the same quarter last year, the firm posted $0.40 EPS. The business’s quarterly revenue was up 1.3% compared to the same quarter last year. Option Care Health has set its FY 2026 guidance at 1.820-1.920 EPS. As a group, analysts predict that Option Care Health, Inc. will post 1.64 EPS for the current year.
Insider Buying and Selling In related news, Director Harry M. Jansen Kraemer, Jr. bought 36,610 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was acquired at an average cost of $21.41 per share, for a total transaction of $783,820.10. Following the purchase, the director owned 450,000 shares in the company, valued at approximately $9,634,500. This represents a 8.86% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Timothy P. Sullivan purchased 24,154 shares of the stock in a transaction dated Thursday, May 7th. The shares were purchased at an average cost of $20.69 per share, for a total transaction of $499,746.26. Following the completion of the acquisition, the director directly owned 73,383 shares in the company, valued at approximately $1,518,294.27. This trade represents a 49.06% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 73,264 shares of company stock worth $1,548,316. 1.70% of the stock is owned by insiders.
Option Care Health Profile (Free Report)
Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.
Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.
Read More Five stocks we like better than Option Care Health These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEDimensional Fund Advisors LP Sells 25,517 Shares of Central Garden & Pet Company $CENTA
NEXT HEADLINE »Dimensional Fund Advisors LP Has $104.99 Million Stock Position in OSI Systems, Inc. $OSIS
July 09, 2026 16:05 ET | Source: Option Care Health, Inc.
BANNOCKBURN, Ill., July 09, 2026 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, today announced that the company will release results for its second quarter ended June 30, 2026 on Wednesday, July 29, 2026 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day.
Conference Call Details
Participants can pre-register for the conference call at the following link: https://register-conf.media-server.com/register/BI808c970d451b4e5ba580364e7e07d20a. The call can also be accessed via a live audio webcast that will be available online at investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.
For Investor Inquiries:
Bob Okunski
Vice President, Investor Relations [email protected]
New York, New York--(Newsfile Corp. - May 11, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Option Care Health, Inc. (NASDAQ: OPCH) ("Option Care Health, Inc.") concerning potential violations of the federal securities laws.
The Q1 2026 earnings report revealed a revenue shortfall against analyst expectations. The Company simultaneously reduced its FY 2026 revenue guidance by up to 3.75% -- a cut of as much as $225 million from the top end of its prior range. The revised outlook of $5.675 billion-$5.775 billion represented a sharp departure from the $5.8 billion-$6.0 billion range that CEO John Rademacher and CFO Meenal Sethna had reaffirmed just 65 days earlier on the Q4 2025 earnings call on February 24, 2026.
The Company cited increased headwinds from the Stelara biosimilar conversion as a contributing factor. On February 24, 2026, CFO Sethna had quantified this headwind at $25 million-$35 million for FY 2026. By April 30, the headwind had increased to $55 million, as "the number of Stelara patients converting to some other therapy" was below expectations, leading to a drop in census and revenue expectations. The projected "400 basis point revenue growth headwind" had quickly jumped to "600 basis points" of CID portfolio headwinds.
If you suffered a loss on your Option Care Health, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004 [email protected]
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296864
On May 7, 2026, Timothy P. Sullivan, Director at Option Care Health (OPCH 2.81%), reported an open-market purchase of 24,154 shares at a weighted-average price of $20.69 per share according to the SEC Form 4 filing.
Transaction summaryMetricValueShares traded24,154Transaction value~$500,000Post-transaction shares (direct)73,383Post-transaction value (direct ownership)~$1.52 millionTransaction value based on SEC Form 4 weighted average purchase price ($20.69); post-transaction value based on May 7, 2026 market close ($20.75).
Key questionsHow does this transaction affect Sullivan’s overall ownership?
This purchase increased Sullivan’s direct holdings by 49.06%, bringing his total direct position to 73,383 shares, with no indirect or derivative holdings reported post-transaction.What is the context of this buy compared to Sullivan’s recent trading activity?
Sullivan’s last reported trade was an open-market purchase of 20,000 shares in August 2025, and this latest acquisition marks the second consecutive period of accumulation after a large sale in August 2024.How does the transaction value compare to Sullivan’s remaining holdings?
The ~$500,000 purchase represents a substantial commitment, with the post-transaction direct holdings valued at approximately ~$1.52 million at the May 7, 2026 market close.What market context surrounded this purchase?
Option Care Health shares have declined 37.9% over the past year (as of May 7, 2026), meaning Sullivan’s increased exposure is occurring at a lower price point compared to prior periods.Company overviewMetricValueRevenue (TTM)$5.67 billionNet income (TTM)$206.19 millionPrice (as of market close 5/7/26)$20.751-year price changeN/A* 1-year price change calculated using May 7th, 2026 as the reference date.
Company snapshotProvides home and alternate site infusion therapies, including anti-infective, immunoglobulin, parenteral and enteral nutrition, and specialty treatments for chronic and acute conditions.Operates a service-based model, generating revenue through clinical care, pharmaceutical dispensing, and nursing services for patients requiring complex infusion therapy outside traditional hospital settings.Serves patients with chronic and acute illnesses, hospitals, physicians, and payers across the United States, focusing on individuals needing ongoing infusion and specialty care.Option Care Health provides home and alternate site infusion services in the United States, has a national footprint, and employs approximately 8,000 people. The company leverages clinical expertise and a broad therapy portfolio to deliver high-touch, cost-effective care for patients with complex medical needs. Its scale, service breadth, and integrated care approach position it as a key partner for healthcare providers and payers seeking quality outcomes in alternate site care delivery.
What this transaction means for investorsThe Form 4 checkbox for a 10b5-1 plan is blank, which matters here. Sullivan's purchase is discretionary — he decided to buy roughly $500,000 worth of OPCH shares on May 7 without a pre-scheduled plan behind it. That carries more signal than a routine plan execution, which is essentially just following prior instructions on a timer. The pattern adds context. Sullivan sold in August 2024, then bought in August 2025, and now again this month. He's rebuilt his stake and then some across two consecutive open-market purchases — and each one has been a deliberate decision, not an automatic one. OPCH has dropped about 38% over the past year, so Sullivan is adding at a meaningfully lower price than prior transactions. Directors don't have the same real-time operational visibility that executives do, but they do sit in the boardroom. Whether insider buying registers in your own process is a personal call — but before it does, the more important thing to watch is whether the company can re-accelerate revenue growth. The CEO flagged it as the central problem last quarter, and EBITDA is already compressing. The insider signal is cleaner than most; the underlying business story still needs to prove itself.
Seena Hassouna has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ:OPCH). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 24, 2026, Option Care Health announced fourth quarter 2025 earnings. On.
Option Care Health executives reaffirmed $5.8B-$6.0B revenue guidance on February 24, 2026, then slashed the range to $5.675B-$5.775B just 65 days later -- a reduction of up to 3.75%.
, /PRNewswire/ -- Shareholders who held Option Care Health (NASDAQ: OPCH) watched nearly 30% of their investment vanish after the company disclosed Q1 2026 results that missed revenue expectations and cut FY 2026 guidance by as much as $225 million from the top of the previously stated range. Those who lost money on OPCH are encouraged to submit their information to Levi & Korsinsky . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
On February 24, 2026, during the Q4 2025 earnings call, CFO Meenal Sethna told investors: "We are reaffirming the guidance we announced in January. We expect full-year 2026 revenue of $5.8 billion to $6 billion." CEO John Rademacher added: "We are confident in the guidance we are putting forth and look forward to continuing our track record of execution." On April 30, 2026 -- just 65 days later -- the company revised FY 2026 revenue guidance downward to $5.675 billion to $5.775 billion, a shortfall of up to $225 million from the prior ceiling.
The February reaffirmation came with a disclosed Stelara biosimilar gross-profit headwind of $25 million to $35 million, with a 400-basis-point revenue growth headwind. The April revision instead attributed "a negative 600 basis point revenue growth headwind … due to the lower CID patient retention and therapy mix." Levi & Korsinsky is investigating whether Option Care Health's prior guidance statements adequately reflected information available to management at the time they were made.
OPCH investors who suffered losses are encouraged to contact Levi & Korsinsky to discuss their legal rights . You may also reach Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.
Frequently Asked Questions About the OPCH Investigation
Q: Who is conducting the OPCH investigation? A: Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of investors who purchased OPCH securities and suffered financial losses. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Option Care Health made materially false or misleading statements regarding its FY 2026 revenue guidance. On February 24, 2026, management reaffirmed a $5.8 billion to $6.0 billion revenue range. On April 30, 2026, the company reduced that range to $5.675 billion to $5.775 billion -- a reduction of up to 3.75%.
Q: How much did OPCH stock drop? A: Shares fell approximately 26.4% by market open on April 30, 2026, after the company reported a Q1 revenue miss and slashed FY 2026 guidance. Investors who purchased shares at higher prices may have sustained significant losses.
Q: What do OPCH investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.
Q: What does it cost me to participate? A: Nothing. Securities investigations are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: What if I already sold my OPCH shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought OPCH and sold at a loss may still participate in the investigation.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Option Care Health stock drops nearly 30% on April 30, 2026, after the company reports a Q1 revenue miss and slashes FY 2026 guidance by up to 3.75% May 14, 2026 09:00 ET | Source: Levi & Korsinsky, LLP
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Option Care Health (NASDAQ: OPCH) shares fell approximately 26.4% by market open and achieved losses of more than 30% at midday following the Company’s Q1 2026 report which disclosed a significant revenue miss below Wall Street expectations and a significant cut to the company’s full-year 2026 revenue guidance from $5.8 billion-$6.0 billion down to $5.675 billion-$5.775 billion. Shareholders who lost money on their OPCH investment are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
Levi & Korsinsky, LLP has initiated an investigation into whether Option Care Health made materially false or misleading statements to investors. On the company's Q4 2025 earnings call on February 24, 2026, CFO Meenal Sethna stated: "We are reaffirming the guidance we announced in January. We expect full-year 2026 revenue of $5.8 billion to $6 billion." CEO John Rademacher added: "We are confident in the guidance we are putting forth and look forward to continuing our track record of execution." Two months later, the company disclosed that FY 2026 revenue would instead fall in the range of $5.675 billion to $5.775 billion -- a reduction of approximately $125 million to $225 million from the previously reaffirmed range.
The investigation is examining the period during which these statements were made and whether investors were adequately informed of the factors -- including a significant increased headwind from the change in patient census, “where [management] had assumed the number of Stelara patients converting to some other therapy … and that didn’t happen.”
If you purchased Option Care Health shares and suffered a loss, click here to discuss your legal rights. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
Frequently Asked Questions About the OPCH Investigation
Q: What is the OPCH securities fraud investigation about? A: A securities fraud investigation has been initiated concerning Option Care Health (NASDAQ: OPCH) regarding potentially materially false and misleading statements about the company's financial outlook. Shares fell more than 25% after the company disclosed a Q1 2026 revenue miss and a substantial downward revision to FY 2026 guidance, causing significant losses for shareholders.
Q: Who is conducting the OPCH investigation? A: Levi & Korsinsky, LLP is investigating potential securities fraud on behalf of investors who purchased OPCH securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.
Q: Who is eligible to participate in the OPCH investigation? A: Investors who purchased OPCH stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do OPCH investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.
Q: What if I already sold my OPCH shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought OPCH and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: Why should investors choose Levi & Korsinsky? A: Ranked among top securities litigation firms by ISS for seven consecutive years. Recovered hundreds of millions for shareholders with extensive federal court experience.
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ:OPCH) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On February 24, 2026, Option Care Health announced fourth quarter 2025 earnings. On the earnings call, the Company’s guidance included a disclosed Stelara biosimilar gross-profit headwind of $25 million to $35 million for FY 2026. The Company also gave full year 2026 revenue guidance of $5.8B-$6.0B. CEO John Rademacher stated: “We are confident in the guidance we are putting forth and look forward to continuing our track record of execution.”
On April 30, 2026, Option Care Health released its first quarter 2026 financial results, including revenue of only $1.35 billion (a 1.3% increase year over year) missing consensus estimates, as well as net income of $45.3 million, down 3.0% year over year, and an adjusted EBITDA of $104.8 million, down 6.3% year over year. The Company also lowered its full year 2026 guidance for revenue from $5.8B-$6.0B to $5.675B - $5.775B. The Company blamed its reduced guidance on “lower CID patient retention and therapy mix.” On this news, the price of Option Care Health shares declined by $6.54 per share, or approximately 24%, from $26.87 per share on April 29, 2026 to close at $20.33 on April 30, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.
If you purchased or otherwise acquired Option Care Health securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Option Care Health, Inc. (NASDAQ: OPCH) resulting from allegations that Option Care Health, Inc. may have issued materially misleading business information to the investing public. So What: If you purchased Option Care Health, Inc. securities you may be entitled to compensation without payment of any out of pocket fees or costs.
Boston, Massachusetts--(Newsfile Corp. - May 18, 2026) - Block & Leviton is investigating Option Care Health, Inc. (NASDAQ: OPCH) for potential securities law violations. Investors who have lost money in their Option Care Health, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/opch.
What is this all about?
Option Care Health, Inc.'s stock fell over 30% on April 30, 2026, after the company reported first quarter results and cut its full year revenue guidance. The company attributed the weaker revenue outlook to a larger than expected patient census reset in its chronic inflammatory disease portfolio, including Stelara biosimilar conversions. Earlier in 2026, Option Care Health maintained its full year revenue guidance and said its related patient census assumptions were aligned with expectations.
Who is eligible?
Anyone who purchased Option Care Health, Inc. common stock and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.
What is Block & Leviton doing?
Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.
What should you do next?
If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at [email protected], or by phone at (888) 256-2510.
Whistleblower?
If you have non-public information about Option Care Health, Inc., you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block & Leviton at [email protected] or by phone at (888) 256-2510.
Why should you contact Block & Leviton?
Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website www.blockleviton.com, call (888) 256-2510 or email [email protected] with any questions.
This notice may constitute attorney advertising.
CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (888) 256-2510
Email: [email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297823
Source: Block & Leviton LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ:OPCH) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 24, 2026, Option Care Health announced fourth quarter 2025 earnings. On the earnings c.
Option Care Health shares lose more than 25% on April 30, 2026, after Q1 2026 revenue falls short of Wall Street expectations and the Company cuts full-year guidance.
, /PRNewswire/ -- Investors who held Option Care Health (NASDAQ: OPCH) shares saw the stock drop 25%-30% after the Company reported Q1 2026 revenue that missed consensus estimates and slashed its FY 2026 revenue outlook from $5.8 billion-$6.0 billion down to $5.675 billion-$5.775 billion. Shareholders who lost money on OPCH are encouraged to submit their information to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
The Q1 2026 earnings report revealed a revenue shortfall against analyst expectations. The Company simultaneously reduced its FY 2026 revenue guidance by up to 3.75% -- a cut of as much as $225 million from the top end of its prior range. The revised outlook of $5.675 billion-$5.775 billion represented a sharp departure from the $5.8 billion-$6.0 billion range that CEO John Rademacher and CFO Meenal Sethna had reaffirmed just 65 days earlier on the Q4 2025 earnings call on February 24, 2026.
The Company cited increased headwinds from the Stelara biosimilar conversion as a contributing factor. On February 24, 2026, CFO Sethna had quantified this headwind at $25 million-$35 million for FY 2026. By April 30, the headwind had increased to $55 million, as "the number of Stelara patients converting to some other therapy" was below expectations, leading to a drop in census and revenue expectations. The projected "400 basis point revenue growth headwind" had quickly jumped to "600 basis points" of CID portfolio headwinds.
If you purchased Option Care Health shares and suffered a loss, click here to discuss your legal rights with Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities investigations and actions. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the OPCH Investigation
Q: How much did OPCH stock drop? A: Shares fell over 25% on April 30, 2026, after the Company reported a Q1 revenue miss and cut FY 2026 revenue guidance by up to 3.75%. Investors who purchased shares at higher prices may be entitled to recovery.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Option Care Health made materially false or misleading statements regarding its FY 2026 revenue outlook and the adequacy of its disclosed headwinds. When actual results diverged sharply from prior guidance, the stock price declined significantly.
Q: Who is eligible to participate in the OPCH investigation? A: Investors who purchased OPCH stock and suffered financial losses may be eligible. Eligibility is based on purchase history and documented losses -- not on whether you still hold the shares.
Q: What do OPCH investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.
Q: What if I already sold my OPCH shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought OPCH and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: Nothing. Securities investigations are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: Has Levi & Korsinsky handled similar cases before? A: Yes, including securities investigations involving revenue guidance revisions, earnings misrepresentation, and executive misconduct across numerous industries.
CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
Ed Korsinsky, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
[email protected] \
Tel: (212) 363-7500\
Fax: (212) 363-7171
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ: OPCH) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON OPTION CARE HEALTH, INC. (OPCH), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About?On April 30, 2026, Option Care Health released.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ: OPCH) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN OPTION CARE HEALTH, INC. (OPCH), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss.
Law Offices of Howard G. Smith continues its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ: OPCH) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN OPTION CARE HEALTH, INC. (OPCH), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On April 30, 2026, Option Care Health released its first quarter 2026 financial results, including revenue of only $1.35 billion (a 1.3% increase year over year) missing consensus estimates, as well as net income of $45.3 million, down 3.0% year over year, and an adjusted EBITDA of $104.8 million, down 6.3% year over year. The Company also lowered its full year 2026 guidance for revenue by approximately $200 million at the mid-point.
On this news, Option Care Health’s stock price fell $6.54, or 24.3%, to close at $20.33 per share on April 30, 2026, thereby injuring investors.
Contact Us To Participate or Learn More:
If you purchased Option Care Health securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: [email protected],
Visit our website at: www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260520900817/en/
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ: OPCH) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON OPTION CARE HEALTH, INC. (OPCH), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happened?On April 30.
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ:OPCH) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On February 24, 2026, Option Care Health announced fourth quarter 2025 earnings. On the earnings call, the Company’s guidance included a disclosed Stelara biosimilar gross-profit headwind of $25 million to $35 million for FY 2026. The Company also gave full year 2026 revenue guidance of $5.8B-$6.0B. CEO John Rademacher stated: “We are confident in the guidance we are putting forth and look forward to continuing our track record of execution.”
On April 30, 2026, Option Care Health released its first quarter 2026 financial results, including revenue of only $1.35 billion (a 1.3% increase year over year) missing consensus estimates, as well as net income of $45.3 million, down 3.0% year over year, and an adjusted EBITDA of $104.8 million, down 6.3% year over year. The Company also lowered its full year 2026 guidance for revenue from $5.8B-$6.0B to $5.675B - $5.775B. The Company blamed its reduced guidance on “lower CID patient retention and therapy mix.” On this news, the price of Option Care Health shares declined by $6.54 per share, or approximately 24%, from $26.87 per share on April 29, 2026 to close at $20.33 on April 30, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.
If you purchased or otherwise acquired Option Care Health securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
On May 29, 2026, Option Care Health Inc OPCH shares fell 3.2%, closing at $20.88. The stock has seen considerable volatility over the past year, with a 52-week high of $36.80 and a low of $18.01.
GF Value™ verdict: Currently priced at $20.88, OPCH is estimated to be 47.9% undervalued compared to its GF Value™ of $40.10. GF Score™ of 81/100 indicates a strong overall ranking, suggesting solid potential for long-term returns. Notable insider activity, with insiders purchasing $1.9 million worth of shares in the last three months, indicating confidence in the company's future. Is OPCH Overvalued or Undervalued? With a GF Value™ of $40.10, Option Care Health Inc OPCH is significantly undervalued at its current price of $20.88. This represents a substantial margin of safety of 47.9%, indicating a potential opportunity for investors. The GF Valuation label suggests that the stock is not only undervalued but also presents a favorable entry point, assuming the company's fundamentals support future growth. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
Despite the attractive valuation, it is essential to consider the risks involved. The stock has experienced significant declines in recent months, with a year-to-date drop of 34.5%. This downward momentum may deter some investors; however, the underlying value indicated by GF Value™ suggests a divergence between market perception and intrinsic worth.
How Does OPCH's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 16.2x 26.6x Forward P/E 11.4x N/A The current P/E (TTM) of 16.2x is significantly below its 5-year median P/E of 26.6x, indicating that the stock is trading at a valuation that is 39% lower than its historical average. This P/E analysis aligns with the GF Value™ verdict, further reinforcing the notion that OPCH is undervalued compared to its historical trading patterns and future earnings potential.
What Does OPCH's GF Score™ Tell Us? Metric Rating GF Score™ 81/100 Financial Strength 6/10 Profitability 7/10 Growth 9/10 Valuation 4/10 Momentum 4/10 The GF Score™ of 81/100 indicates a robust overall assessment of Option Care Health Inc OPCH , with strong growth potential (9/10) being its standout feature. However, the valuation rank of 4/10 suggests some concerns regarding its current pricing relative to earnings. The financial strength of 6/10 and profitability rank of 7/10 indicate a stable financial position, but the lower momentum rank may reflect recent market performance challenges.
What Are Insiders Doing with OPCH Stock? In the past three months, insiders have demonstrated confidence in Option Care Health Inc by purchasing $1.9 million worth of shares, with no recorded sales. This pattern of insider buying can be a positive signal, suggesting that those with the most intimate knowledge of the company believe in its future prospects. Such actions often reflect a belief in the underlying value and potential for recovery or growth, despite the current market pressures.
What This Means for Investors Based on the GF Value™ assessment indicating that OPCH is 47.9% undervalued, the stock presents a potential opportunity for investors looking for value plays in the healthcare sector. However, the recent price performance and market volatility warrant a cautious approach, considering the risks inherent in the current market environment.
For the complete analysis, visit the Option Care Health Inc OPCH stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is OPCH's GF Score™?
OPCH's GF Score™ is 81/100, indicating a strong overall ranking that suggests solid potential for long-term returns based on key performance metrics.
Is OPCH overvalued or undervalued?
According to the GF Value™ assessment, OPCH is undervalued at its current price of $20.88, which is significantly below its estimated fair value of $40.10.
What is OPCH's P/E ratio?
OPCH has a P/E (TTM) of 16.2x, which is considerably lower than its 5-year median P/E of 26.6x, confirming that the stock is trading at a lower valuation than its historical averages.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
June 01, 2026 07:00 ET | Source: Option Care Health, Inc.
BANNOCKBURN, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Option Care Health is proud to announce it has been ranked No. 15 on the World’s Most Impactful Companies 2026 list, a global recognition of organizations delivering measurable positive impact across society, the environment, and the economy. This recognition is presented by TIME and Statista, global leaders in data analysis and industry benchmarking, and it can now be viewed on time.com.
Being named to the World’s Most Impactful Companies 2026 list signifies that Option Care Health stands among a select group of organizations driving meaningful change through their core business activities. Unlike perception-based assessments or self-reported sustainability claims, this ranking is grounded in a rigorous, science-based methodology. The Upright Project’s Net Impact Model evaluates companies based on the net-positive contributions of their products and services across four key dimensions: Society, Knowledge, Health, and Environment.
Inclusion in this ranking represents an independent, third-party endorsement of Option Care Health’s measurable impact, reinforcing its commitment to responsible business practices and strengthening trust among customers, team members, partners, and the broader public. It highlights the company’s ability to create value not only for shareholders, but for society at large.
John C. Rademacher, President and CEO of Option Care Health, shared, “Our purpose is to provide extraordinary care that changes lives. That commitment drives everything we do from supporting our patients to shaping the future of healthcare. We’re incredibly proud to be recognized as #15 on TIME's World’s Most Impactful Companies list. This recognition reflects the meaningful impact our team members make every day. We never lose sight of the fact that behind every dose dispensed and every nursing visit is a loved one and we’re honored to make a difference when it matters most.”
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.
June 04, 2026 07:00 ET | Source: Option Care Health, Inc.
BANNOCKBURN, Ill., June 04, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced the appointment of Robert Okunski as Vice President, Investor Relations effective May 26, 2026.
In this role, Okunski will lead the Company’s investor relations strategy and serve as the primary liaison between Option Care Health and the investment community. He will be responsible for communicating the Company’s business strategy, financial performance, capital allocation priorities and long-term growth opportunities to investors, analysts and other key stakeholders.
“Bob brings more than two decades of investor relations leadership experience across healthcare, technology and energy industries,” said Meenal Sethna, Chief Financial Officer of Option Care Health. “His proven track record of building best-in-class investor relations programs, strengthening investor engagement and enhancing transparency, elevating corporate visibility, will be invaluable as we continue to execute our growth strategy and create long-term shareholder value.”
Okunski joins Option Care Health from Enhabit Home Health & Hospice, where he served as Vice President of Investor Relations. During his tenure, he led the company’s investor relations strategy, enhanced engagement with institutional investors and analysts, and increased the company’s visibility within the investment community.
Prior to Enhabit, Okunski held senior investor relations leadership positions at Velo3D Inc., SunPower Corporation, Spansion Inc. and PeopleSoft.
Okunski holds a Master of Business Administration from Moravian University and a Bachelor of Arts from Colgate University.
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.
